IHS Chemical Week

Regions :: North Asia :: Korea

Merck & Co. and Hanwha Chemical to Develop Biosimilar Candidate

12:00 AM MDT | June 14, 2011 | Deepti Ramesh

Merck & Co. (Whitehouse Station, NJ) says it has entered into an exclusive global agreement with Hanwha Chemical (Seoul) to develop and commercialize a candidate biosimilar form of Enbrel (etanercept). Hanwha Chemical, through its Bio business unit, and Merck, through a subsidiary, will work together to develop and commercialize HD203, a candidate biosimilar form of etanercept developed by Hanwha, under the terms of the agreement. Merck will conduct clinical development and be responsible for manufacturing. Merck will commercialize HD203 globally, except for...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa